Lytix Biopharma AS
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
LYTIX | OL
Overview
Corporate Details
- ISIN(s):
- NO0010405780
- LEI:
- 549300NXMIMRSBCDZO71
- Country:
- Norway
- Address:
- Sandakerveien 138, 0484 OSLO
- Website:
- https://www.lytixbiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lytix Biopharma AS is a clinical-stage immuno-oncology company developing novel cancer immunotherapies based on its proprietary technology platform. The platform utilizes host-defense peptide-derived molecules engineered to kill cancer cells and stimulate a targeted anti-tumor immune response. The company's lead product candidate, LTX-315, is an oncolytic peptide being evaluated in various clinical trials, including for Basal Cell Carcinoma. Lytix's therapeutic agents are designed for use as monotherapies and in combination with other treatments, such as checkpoint inhibitors and cell therapies, to enhance their efficacy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-11 07:00 |
Regulatory News Service
Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Me…
|
English | 641.5 KB | ||
| 2025-11-11 07:00 |
Regulatory News Service
Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhosp…
|
Norwegian | 170.6 KB | ||
| 2025-11-11 07:00 |
Regulatory News Service
Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Me…
|
English | 5.5 KB | ||
| 2025-11-11 07:00 |
Regulatory News Service
Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhosp…
|
Norwegian | 4.8 KB | ||
| 2025-11-10 07:00 |
Regulatory News Service
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 F…
|
English | 1.2 MB | ||
| 2025-11-10 07:00 |
Regulatory News Service
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 F…
|
English | 634.6 KB | ||
| 2025-11-10 07:00 |
Regulatory News Service
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 F…
|
English | 4.2 KB | ||
| 2025-10-10 11:46 |
Report Publication Announcement
Financial calendar
|
English | 430 bytes | ||
| 2025-10-10 11:46 |
Report Publication Announcement
Finansiell kalender
|
Norwegian | 417 bytes | ||
| 2025-10-08 07:00 |
Regulatory News Service
Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data f…
|
English | 646.0 KB | ||
| 2025-10-08 07:00 |
Regulatory News Service
Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data f…
|
English | 3.6 KB | ||
| 2025-08-28 07:00 |
Earnings Release
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 642.2 KB | ||
| 2025-08-28 07:00 |
Investor Presentation
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 2.7 MB | ||
| 2025-08-28 07:00 |
Interim Report
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 1.1 MB | ||
| 2025-08-28 07:00 |
Earnings Release
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 4.9 KB |
Automate Your Workflow. Get a real-time feed of all Lytix Biopharma AS filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lytix Biopharma AS
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lytix Biopharma AS via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
